26th Annual International Congress on Hematologic Malignancies

The 26th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is not to be missed!

Now in its 26th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.

Learning Objectives

The learning objectives of this program are:

• Assess current and emerging biomarkers to determine risk and choose therapy for patients with hematologic malignancies
• Integrate key clinical data on current treatment approaches for the management of patients with hematologic malignancies and benign hematologic disorders
• Discuss recent clinical trial results on emerging therapeutic approaches for patients with hematologic malignancies
• Describe approaches to mitigate and manage treatment-related adverse events in patients with hematologic malignancies
• Evaluate clinical implications of evolving therapeutic paradigms in hematologic malignancies

Use code WHEM35CME for 35 percent off!

Program Chairs

Andre H. Goy, MD
Chairman and Director
Chief, Division of Lymphoma
John Theurer Cancer Center
Chief Science Officer
Regional Cancer Care Associates
Hackensack, NJ
Lydia Pfund Chair for Lymphoma
Professor of Medicine
Georgetown University
Washington, DC

Jorge E. Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Alliance
Augusta University
Augusta, GA

Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology & Medical Oncology
Emory School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA